BNTX:NASDAQ
BioNTech SE - ADR
$96.73
arrow_upward
+0.34%(+0.33) 1D
$97.50
arrow_upward
+0.80% (+0.77)bedtimeAfter hours
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$96.77
High
$97.90
Low
$96.00
Mkt. cap
24.30B
Avg. vol.
1.54M
Volume
1.18M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.79
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$96.77
High
$97.90
Low
$96.00
Mkt. cap
24.30B
Avg. vol.
1.54M
Volume
1.18M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.79
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
6 hours ago
BioNTech's Handover Year: Insider Selling, a Halved Revenue Base, and a Pipeline Under the Microscop
ad-hoc-news.de
·
1 day ago
BioNTech's Two-Year Gap: A Halved COVID Business, a Failed Colon Trial, and a CEO Selling on Schedul
Pluang
·
2 days ago
Moderna stock jumps 8% on momentum despite no n...
Simply Wall Street
·
2 days ago
BioNTech (BNTX) Stock Stays Rich On Sales As Revenue Looks Weaker
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR